DGIdb - AC-480 Drug Record

AC-480 chembl:CHEMBL1645462 Antineoplastic

Alternate Names:

AC480
AC-480
BMS-599626
BMS 599626

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Class	Kinase Inhibitors

(4 More Sources)

Publications:

Soria et al., 2012, Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors., Ann. Oncol.
Gavai et al., 2009, Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases., J. Med. Chem.

AC-480 ERBB4

Interaction Score: 1.87

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions
AC-480 ERBB2

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Established target

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

PMIDs:
21576284 19821562

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD
AC-480 EGFR

Interaction Score: 0.83

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Established target

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

PMIDs:
19821562 21576284

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD
AC-480 ERBB3

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

MyCancerGenome: BMS-599626
- Version: 20-Jun-2017
Alternate Names:

BMS-599626 Development Name

AC480 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: AC480
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

DTC: AC-480

Version: 02-September-2020

Alternate Names:

CHEMBL1645462 ChEMBL Drug ID

Drug Info:

Publications:

Gavai et al., 2009, Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases., J. Med. Chem.

JAX-CKB: AC480

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Soria et al., 2012, Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors., Ann. Oncol.

TALC: BMS-599626
- Version: 12-May-2016
Alternate Names:

BMS-599626 Primary Drug Name

BMS-599626 Drug Synonym

Drug Info:

Publications:
TTD: BMS-599626
- Version: 2020.06.01
Alternate Names:

D0U4FF TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1645462
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1645462
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	AC480
Novel drug target	Novel Target
Mechanism of Interaction	Receptor protein-tyrosine kinase erbB-4 inhibitor

AC-480 Drug Record

AC-480 chembl:CHEMBL1645462 Antineoplastic

Alternate Names:

Drug Info:

Publications:

AC-480 ERBB4

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name AC480 Novel drug target Novel Target Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

AC-480 ERBB2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name AC480 Novel drug target Established target Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

PMIDs: 21576284 19821562

Sources: TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

AC-480 EGFR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name AC480 Novel drug target Established target Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

PMIDs: 19821562 21576284

Sources: TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

AC-480 ERBB3

Interaction Types & Directionality: n/a

Interaction Info: Trial Name AC480 Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

MyCancerGenome: BMS-599626

Alternate Names: BMS-599626 Development Name AC480 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: AC480

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

DTC: AC-480

Alternate Names: CHEMBL1645462 ChEMBL Drug ID

Drug Info:

JAX-CKB: AC480

Alternate Names:

Drug Info:

Publications: Soria et al., 2012, Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors., Ann. Oncol.

TALC: BMS-599626

Alternate Names: BMS-599626 Primary Drug Name BMS-599626 Drug Synonym

Drug Info:

Publications:

TTD: BMS-599626

Alternate Names: D0U4FF TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1645462

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1645462

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Established target

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

PMIDs:
21576284 19821562

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Established target

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

PMIDs:
19821562 21576284

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Alternate Names:

BMS-599626 Development Name

AC480 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL1645462 ChEMBL Drug ID

Publications:

Soria et al., 2012, Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors., Ann. Oncol.

Alternate Names:

BMS-599626 Primary Drug Name

BMS-599626 Drug Synonym

Alternate Names:

D0U4FF TTD Drug ID